INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,132,998 | +107.4% | 112,650 | +77.4% | 0.99% | +106.0% |
| Q1 2023 | $3,439,067 | -43.3% | 63,510 | -44.5% | 0.48% | -42.0% |
| Q4 2022 | $6,061,139 | +54.0% | 114,534 | +35.4% | 0.83% | +57.4% |
| Q3 2022 | $3,936,000 | -79.0% | 84,584 | -74.2% | 0.53% | -79.3% |
| Q2 2022 | $18,716,000 | +9.9% | 327,894 | +17.8% | 2.54% | +32.9% |
| Q1 2022 | $17,035,000 | +3478.8% | 278,395 | +2170.8% | 1.91% | +166.4% |
| Q2 2016 | $476,000 | – | 12,260 | – | 0.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |